OS Therapies (OSTX) Short term Debt (2023 - 2024)

OS Therapies' (OSTX) quarterly Short term Debt came in at $250000.0 in Q2 2024, up 150.0% on a QoQ basis from $100000.0 in Q1 2024.

OS Therapies (OSTX) Short term Debt (2023 - 2024) Analysis & Trends

OS Therapies (OSTX) has 2 years of Short term Debt data on file, last reported at $250000.0 in Q2 2024.

Quarterly Short term Debt changed N/A year-over-year to $250000.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $250000.0 (changed N/A YoY) and the FY2023 annual result came in at $1.4 million, changed N/A from the prior year.
Short term Debt rose to $250000.0 in Q2 2024, from $100000.0 in the prior quarter.
In the past five years, Short term Debt ranged from a high of $1.4 million in Q4 2023 to a low of $100000.0 in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.71 Bn	131.86 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.55 Bn	78.55 Bn	3.93 Bn
3	Argenx Se	65.26 Bn	60.07 Bn	1.37 Bn
4	Moderna	59.81 Bn	54.67 Bn	52.00 Mn
5	BeOne Medicines	42.16 Bn	37.06 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.87 Bn	28.56 Bn	992.69 Mn
7	BioNTech SE	28.13 Bn	9.74 Bn	668.28 Mn
8	Insmed	27.53 Bn	26.37 Bn	358.27 Mn
9	Royalty Pharma	27.31 Bn	26.47 Bn	-
10	OS Therapies	19.56 Mn	19.56 Mn	-

Download Data